Fusilev sales boosts Spectrum, but analysts warn of fragility
This article was originally published in Scrip
Spectrum Pharmaceuticals has reported increasing demand for its anticancer Fusilev (levolecovorin), and has increased its manufacturing capacity anticipating that the demand will "continue throughout 2012 and beyond". The company appears to be benefitting from a continuing generic leucovorin shortage. However, some analysts believe that uncertainties in the supply of generic leucovorin in the coming months could mean that Spectrum's revenue potential is fragile.